NYSE · TEVA

Teva Pharmaceutical Industries Limited American

$31.39 +$0.58 (+1.88%) 1D Market open
Charting by TradingView

Key Metrics

$35.88B
Market cap
22.92×
P/E · TTM
$17.35B
Revenue · TTM
$1.57B
Net income
EPS · TTM $1.35
Dividend yield —
Free cash flow $1.17B
Beta · 1Y 0.82
EBITDA · TTM —
Gross margin 52.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 29
    The stock moved +11.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 29

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$35.88B
Enterprise value$34.73B
Shares outstanding1.2B
52-wk range$14.99 – $37.35
Avg volume · 20D9.8M
Net cash $1.14B
Book value / share$7.10
IndustryPharmaceutical Preparations
ExchangeNYSE
About Teva Pharmaceutical Industries Limited American
IPO dateFeb 16, 1982
Employees32842

Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E22.92
P/S2.07
P/FCF30.61
EV/EBITDA—
EV/Sales2.00
Graham №$14.69

Profitability

Gross 52.1%
Operating 13.2%
Net 9.0%
FCF 6.8%
ROE / ROIC 23.0% · 36.7%

Financial Health

Current ratio1.01
Quick ratio0.78
Debt / equity0.32
Debt / EBITDA —
Net cash $1.14B
Working capital$178.00M

Cash Flow · TTM

Operating CF $1.71B
Capex −$542.00M
Free cash flow $1.17B
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

7 / 9
Strong fundamentals · 7 of 9 signals passing

Altman Z-Score

0.8
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$14.69 vs $31.08
Trades 2.1× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings